
**Prostate Cancer Tumor Growth dataset cited in Tito Fojo et al.'s *The Lancet Oncology* Manuscript:
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate
cancer**

Protocols and Case Report Forms can be obtained on www.ProjectDataSphere.org for the source datasets included in this curated dataset. The source datasets are listed in the table below:

Descriptive Information of Control Arms from Eight Randomized Clinical Trials in mCRPC available in Project Data Sphere

PDS Trial Nomenclature	Trial Name [Experimental agent being tested]	Treatment	Patients on treatment	Patients with PSA data	Blinding Method	Cancer Stage	Study Phase	Study Start	Study End	ClinicalTrial.gov ID
Pfizer 08 81 ^{1, A}	[sunitinib]	PRN	284	277	Double-Blinded	IV	III	7/2008	12/2011	NCT00676650
CougarB 2008 101 ^{2, A}	[abiraterone acetate]	PRN	398	377	Double-Blinded	IV	III	5/2008	10/2012	NCT00638690
Sanofi 2007 79 ³	TROPIC [cabazitaxel]	MIT+PRN	371	369	Open Label Study	IV	III	1/2007	9/2009	NCT00417079
Sanofi 2000 80 ⁴	[docetaxel]	MIT+PRN	337	332	Open Label Study	IV	III	3/2000	6/2002	N/A
Centoco 2006 98 ⁵	[siltuximab]	MIT+PRN	49	46	Open Label Study	IV	IIB	11/2006	11/2008	NCT00385827
Sanofi 2007 83 ⁶	VENICE [afilbercept]	DOC+PRN	604	589	Double-Blinded	IV	III	8/2007	4/2012	NCT00519285
Novacea 2006 89 ⁷	ASCENT-2 [DN-101]	DOC+PRN	451	443	Double-Blinded	IV, III	III	1/2006	11/2007	NCT00273338
Celgene 2009 90 ⁸	MAINSAIL [lenalidomide]	DOC+PRN	526	525	Double-Blinded	IV	III	11/2009	11/2016	NCT00988208

Abbreviations: PRN, prednisone; MIT, mitoxantrone; DOC, docetaxel

^ASecond line of therapy
